Metronidazole (Paediatric)
Brand names: Flagyl, Metronidazole Suspension
Metronidazole (paediatric) is an antimicrobial used in children for anaerobic bacterial infections and certain protozoal infections, including intra-abdominal and dental infections, C. difficile and giardiasis. This page covers its use in the paediatric population.
Adult dose
Paediatric dose
Dose adjustments
'The elimination half-life of metronidazole remains unchanged in the presence of renal failure. The dosage of metronidazole therefore needs no reduction.' Such patients retain the metabolites of metronidazole, the clinical significance of which is not known. In patients undergoing haemodialysis, metronidazole and its metabolites are efficiently removed during an eight-hour dialysis period, so metronidazole should be re-administered immediately after haemodialysis. No routine dose adjustment is needed in renal failure patients undergoing intermittent peritoneal dialysis or CAPD. Substantial impairment of metronidazole clearance may occur in advanced hepatic insufficiency, with significant accumulation in hepatic encephalopathy (§4.4).
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
The 7.5 mg/kg figure is the per-DOSE component of the divided regimen for established anaerobic infection. VERBATIM §4.2: children over 8 weeks to 12 years of age — 'The usual daily dose is 20-30mg/kg/day as a single dose or divided into 7.5mg/kg every 8 hours. The daily dose may be increased to 40mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.' Children under 8 weeks of age — '15mg/kg as a single dose daily or divided into 7.5mg/kg every 12 hours.' In newborns with a gestational age under 40 weeks, accumulation can occur during the first week of life, so serum metronidazole concentrations should preferably be monitored after a few days of therapy. SURGICAL PROPHYLAXIS: children under 12 years — 20–30 mg/kg as a single dose given 1–2 hours before surgery; newborns with a gestational age under 40 weeks — 10 mg/kg body weight as a single dose before operation. PROTOZOAL INFECTIONS (fixed doses by age band, §4.2 table): trichomoniasis in children — 40 mg/kg orally as a single dose or 15–30 mg/kg/day divided in 2–3 doses; giardiasis children 7–10 years 600–800 mg once daily, 3–7 years 500 mg once daily, or alternatively 15–40 mg/kg/day divided in 2–3 doses; amoebiasis, gingivitis and other indications have separate fixed doses for the 7–10, 3–7 and 1–3 year bands. 'Children and infants weighing less than 10 kg should receive proportionally smaller dosages.' Verify all under-18 dosing against a children's formulary.
Contraindications
- Known hypersensitivity to nitroimidazoles, metronidazole or any of the excipients
Side effects
- Nausea, vomiting, epigastric pain, diarrhoea, taste disorders, oral mucositis and furred tongue (frequency not known)
- Peripheral sensory neuropathy or transient epileptiform seizures during intensive and/or prolonged therapy — in most cases neuropathy disappeared after treatment was stopped or the dose reduced; also drowsiness, dizziness, convulsions and headaches (very rare)
- Encephalopathy and subacute cerebellar syndrome (ataxia, dysarthria, gait impairment, nystagmus, tremor), which may resolve on discontinuation (very rare); aseptic meningitis (not known)
- Increase in liver enzymes, cholestatic or mixed hepatitis, hepatocellular liver injury, jaundice and pancreatitis, reversible on drug withdrawal (very rare); severe hepatotoxicity/acute hepatic failure in patients with Cockayne syndrome (§4.4)
- Skin rashes, pustular eruptions, acute generalised exanthematous pustulosis, pruritus and flushing (very rare); erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and fixed drug eruption (not known); darkening of urine due to a metronidazole metabolite (very rare)
Interactions
- Disulfiram — psychotic reactions reported in alcoholic patients using metronidazole and disulfiram concurrently; metronidazole should not be given to patients who have taken disulfiram within the last two weeks (US label, Drug Interactions)
- Alcoholic beverages or products containing propylene glycol — abdominal cramps, nausea, vomiting, headaches and flushing may occur during or following metronidazole therapy (US label)
- Warfarin and other oral coumarin anticoagulants — anticoagulant effect potentiated with prolongation of prothrombin time; monitor prothrombin time and INR carefully (US label)
- Lithium — short-term metronidazole in patients on relatively high doses of lithium has been associated with elevated serum lithium and signs of lithium toxicity; check serum lithium and creatinine several days after starting metronidazole (US label)
- Busulfan — plasma concentrations of busulfan increased, with increased risk of busulfan toxicity (US label)
- NOTE: the UK SPC §4.5 interaction section was NOT retrieved in this source bundle — the interactions above are taken from the US label and must be verified against the UK SPC
Clinical monograph
How it works
Within susceptible anaerobic bacteria and protozoa it is reduced to reactive intermediates that damage microbial DNA, leading to cell death.
Prescribing in practice
- The most important paediatric counselling point is that alcohol (including in liquid medicines and some mouthwashes) must be avoided during and shortly after treatment because of a disulfiram-like reaction.
- Prolonged or repeated courses carry a risk of peripheral and central neurotoxicity, so duration should be limited and the indication reviewed.
- Dose is weight-based and available by oral, intravenous and rectal routes; doses should be confirmed against a children's formulary, with caution in hepatic impairment.
Monitoring
Monitor for neurological symptoms (numbness, tingling, ataxia) and hepatic function on prolonged courses, alongside clinical response.
Counselling the patient
- Avoid all alcohol during the course and for a short period afterwards to prevent flushing, nausea and palpitations.
- Report any numbness, tingling, unsteadiness or persistent headache.
- Complete the full course as prescribed even if the child feels better.
Evidence & guidelines
Metronidazole is a long-established first-line agent for anaerobic and several protozoal infections, with its alcohol interaction and neurotoxicity risk well documented.
Reference: NICE NG199 (C. difficile); PHE Antibiotic Guidelines; IDSA/SHEA C. difficile Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- PICU Delirium Assessment (pCAM-ICU) · Delirium Assessment
- Vasoactive-Inotropic Score (VIS) · Inotropic Support
- Lund-Browder Chart — TBSA Burn Estimation · Burns
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- IE Prophylaxis Indication · Treatment
- Kocher Criteria for Septic Arthritis · Bone & Joint Infection